A5016061964- Liver Disease Diagnosis and Treatment
- Hepatitis B Virus Studies
- Hepatitis C virus research
- Liver Disease and Transplantation
- Liver Diseases and Immunity
- HIV/AIDS drug development and treatment
- Hepatitis Viruses Studies and Epidemiology
- Hepatocellular Carcinoma Treatment and Prognosis
- Organ Transplantation Techniques and Outcomes
- Cytomegalovirus and herpesvirus research
- Gallbladder and Bile Duct Disorders
- Viral gastroenteritis research and epidemiology
- Pediatric Hepatobiliary Diseases and Treatments
- Blood groups and transfusion
- Transplantation: Methods and Outcomes
- Renal Transplantation Outcomes and Treatments
- COVID-19 Clinical Research Studies
- Chronic Lymphocytic Leukemia Research
- Alcohol Consumption and Health Effects
- Iron Metabolism and Disorders
- Cancer Immunotherapy and Biomarkers
- Viral-associated cancers and disorders
- Immunodeficiency and Autoimmune Disorders
- Pneumocystis jirovecii pneumonia detection and treatment
- Metabolism and Genetic Disorders
Ospedale San Giuseppe
2016-2025
Ospedale Papa Giovanni XXIII
2023-2025
University of Milano-Bicocca
2000-2025
University of Milan
2015-2024
MultiMedica
2005-2024
Humanitas University
2018-2023
Humanitas Gavazzeni
2023
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
2007-2016
Istituti di Ricovero e Cura a Carattere Scientifico
1997-2016
Istituto Ortopedico Gaetano Pini
2016
Progression of hepatitis B in patients with lamivudine-resistant strains is slowed down by adefovir dipivoxil (ADV). Whether the time point ADV administration (genotypic vs. phenotypic resistance) influences outcome therapy unknown. We compared e antigen (HBeAg)-negative chronic genotypic and resistance to lamivudine. Ten milligrams was administered daily for 2 years 46 HBeAg-negative at (group A, >6 log10 copies/mL virus [HBV] DNA high alanine aminotransferase [ALT] levels) 28 B, 3-6...
Interleukin (IL)28B polymorphisms have been associated with interferon (IFN)-induced viral clearance in patients chronic hepatitis C. Whether this is also true for the difficult-to-cure B e antigen (HBeAg)-negative (CHB) unknown. One hundred and one HBeAg-negative (92% genotype D) compensated CHB (84% males, 46 years; virus [HBV] DNA: 6.0 log cp/mL; alanine aminotransferase [ALT]: 136 IU/L; 42% cirrhosis) were followed up a median of 11 years (range, 1-17) after 23 months 10-48) either...
<h3>Objective</h3> Treatment with peginterferon α-2a (PegIFN) for 48 weeks is the standard of care selected HBeAg-negative patients chronically infected hepatitis B virus (HBV), but limited treatment efficacy. A study was undertaken to investigate whether extension 96 improves outcome in this patient population. <h3>Methods</h3> 128 (120 genotype D) were randomised weekly 180 μg PegIFN (group A, n=51), followed by 135 an additional B, n=52) or plus lamivudine (100 mg/day) then C, n=25)....
The outbreak of coronavirus disease 2019 (COVID-19) has distressed our working practice. Infectious specialists, pneumologists and intensivists were not enough to face the enormous amount patients that needed hospital care; therefore, many doctors have been recruited from other medical specialties trying take care as possible. 'call duty' such for urgent COVID-19 cases, however, diverted attention with chronic conditions, which might neglected or undervalued. In this extremely difficult...
•Under real-world conditions, OCA was effective in ~43% of patients who were non-responders to UDCA, according Poise criteria.•Patients with cirrhosis showed lower efficacy (29.5%), mainly attributed reduced tolerability and higher discontinuation rate.•Patients overlap AIH-PBC a comparable pure PBC, ALT reduction at 6 months.•Most PBC are still need additional therapy if aiming normalise liver biochemistry. Background & aimsObeticholic acid (OCA) is the second-line treatment approved for...
Steatosis is a common histopathological feature of chronic hepatitis B (CHB) and has been associated with severity liver disease. Recently, the rs738409 I148M patatin-like phospholipase domain-containing 3 (PNPLA3) polymorphism demonstrated to influence steatosis susceptibility fibrosis progression in patients different diseases, but no data are yet available for CHB. The aim this study was evaluate whether PNPLA3 influences large series We enrolled 235 treatment-naïve CHB consecutively...
Protein induced by vitamin K absence or antagonist-II (PIVKA-II) has been suggested as a serum biomarker for hepatocellular carcinoma (HCC) in Asian hepatitis B virus (HBV)-treated subjects but no studies tested it Caucasian cirrhotics long-term nucleos(t)ide analogues (NUCs)-treated. We assessed the detection accuracy of PIVKA-II alone combination with alpha-foetoprotein (AFP) patients under surveillance.This cross-sectional, single centre case-control study was conducted 212 NUC-treated...
Patients with resolved hepatitis B virus (HBV) infection, i.e., surface antigen (HBsAg)-negative/antihepatitis core (anti-HBc)-positive, undergoing rituximab (RTX)-based chemotherapy for hematological malignancies without anti-HBV prophylaxis are at risk of HBV reactivation, but the in such patients receiving RTX rheumatological disorders is not clear. We evaluated this HBsAg-negative/anti-HBc-positive rheumatoid arthritis (RA) prophylaxis.Thirty-three outpatients RA undetectable DNA by...